-
Je něco špatně v tomto záznamu ?
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer, pretreated with endocrine therapy: results of the phase 3 ember-3 trial
Komal L. Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O'Shaughnessy, Nadia Harbeck, Lisa A. Carey, Giuseppe Curigliano, Antonio Llombart-Cussac, Elgene Lim, María de la Luz...
Status neindexováno Jazyk angličtina Země Česko
Typ dokumentu abstrakt z konference
- Publikační typ
- abstrakt z konference MeSH
Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea
Baylor University Medical Center Texas Oncology US Oncology Dallas TX USA
Breast Center Department of Obstetrics and Gynecology and CCC Munich
Department of Breast Surgery Chiba Cancer Center Hospital Chiba Japan
Division of Breast Surgery Department of Surgery Taichung Veterans General Hospital Taichung Taiwan
Eli Lilly and Company Indianapolis IN USA
Filios Alta Medicina SA de CV Neuvo León Mexico
Harbin Medical University Cancer Hospital Harbin China
Hospital Arnau de Vilanova Valencia Spain
Hospital de Oncología Centro Médico Nacional Siglo XXI Ciudad de Mexico Mexico
Hospital Maria Curie Buenos Aires Argentina
Institut Jules Bordet Hôpital Universitaire de Bruxelles Brussels Belgium
Institute Curie and UVSQ Paris Saclay University Paris and Saint Cloud France
LMU University Hospital Munich Germany
Mastology Department Women's Health Hospital São Paulo Brazil
Medical Oncology Department Hospital Universitario Virgen del Rocío Seville Spain
Memorial Sloan Kettering Cancer Center
National Hospital Organization Kyushu Cancer Center Fukuoka Japan
National Taiwan University Hospital and National Taiwan University College of Medicine Taipei Taiwan
University Hospital Leuven Leuven Belgium
University of Milan Italy and European Institute of Oncology IRCCS Milan Italy
University of North Carolina at Chapel Hill Chapel Hill NC USA
Vall d'Hebron University Hospital Vall d'Hebron Institute of Oncology Barcelona Spain
Weill Cornell Medical College New York NY USA
Yonsei University College of Medicine Seoul Republic of Korea
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25020238
- 003
- CZ-PrNML
- 005
- 20251008150225.0
- 007
- ta
- 008
- 251006s2025 xr f 000 0|eng||
- 009
- PC
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Jhaveri, Komal L. $u Memorial Sloan Kettering Cancer Center; and Weill Cornell Medical College, New York, NY, USA
- 245 10
- $a Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer, pretreated with endocrine therapy: results of the phase 3 ember-3 trial / $c Komal L. Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O'Shaughnessy, Nadia Harbeck, Lisa A. Carey, Giuseppe Curigliano, Antonio Llombart-Cussac, Elgene Lim, María de la Luz García Tinoco, Joohyuk Sohn, Andre Mattar, Qingyuan Zhang, Chiun-Sheng Huang, Chih-Chiang Hung, Jorge Luis Martinez Rodriguez, Manuel Ruiz Borrego, Rikiya Nakamura, Kamnesh R. Pradhan, Christoph Cramer von Laue, Emily Barrett, Shanshan Cao, Xuejing Aimee Wang, Lillian Smyth, Francois-Clement Bidard, Vladimir Habetinek (non-author presenter)
- 590 __
- $a NEINDEXOVÁNO
- 655 _7
- $a abstrakt z konference $2 czmesh $7 D016416
- 700 1_
- $a Neven, Patrick $7 xx0061606 $u University Hospital Leuven, Leuven, Belgium
- 700 1_
- $a Casalnuovo, Monica Lis $u Hospital Maria Curie, Buenos Aires, Argentina
- 700 1_
- $a Kim, Sung-Bae $u Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
- 700 1_
- $a Tokunaga, Eriko $u National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
- 700 1_
- $a Aftimos, Philippe $u Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium
- 700 1_
- $a Saura, Cristina $u Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 700 1_
- $a O'Shaughnessy, Joyce $7 xx0109620 $u Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, USA
- 700 1_
- $a Harbeck, Nadia $7 xx0276121 $u Breast Center, Department of Obstetrics and Gynecology, and CCC Munich; LMU University Hospital, Munich, Germany
- 700 1_
- $a Carey, Lisa A. $u University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
- 700 1_
- $a Curigliano, Giuseppe $u University of Milan, Italy and European Institute of Oncology, IRCCS, Milan, Italy
- 700 1_
- $a Llombart-Cussac, Antonio $u Hospital Arnau de Vilanova, Valencia, Spain
- 700 1_
- $a Lim, Elgene $u Garvan Institute of Medical Research and University of New South Wales, Darlinghurst, Sydney, New South Wales, Australia
- 700 1_
- $a Luz García Tinoco, María de la $u Hospital de Oncología, Centro Médico Nacional Siglo XXI, Ciudad de Mexico, Mexico
- 700 1_
- $a Sohn, Joohyuk $u Yonsei University College of Medicine, Seoul, Republic of Korea
- 700 1_
- $a Mattar, Andre $u Mastology Department, Women's Health Hospital, São Paulo, Brazil
- 700 1_
- $a Zhang, Qingyuan $u Harbin Medical University Cancer Hospital, Harbin, China
- 700 1_
- $a Huang, Chiun-Sheng $u National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
- 700 1_
- $a Hung, Chih-Chiang $u Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital, Taichung Taiwan
- 700 1_
- $a Martinez Rodriguez, Jorge Luis $u Filios Alta Medicina SA de CV, Neuvo León Mexico
- 700 1_
- $a Borrego, Manuel Ruiz $u Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville Spain
- 700 1_
- $a Nakamura, Rikiya $u Department of Breast Surgery, Chiba Cancer Center Hospital, Chiba, Japan
- 700 1_
- $a Pradhan, Kamnesh R. $u Eli Lilly and Company, Indianapolis, IN, USA
- 700 1_
- $a Laue, Christoph Cramer von $u Eli Lilly and Company, Indianapolis, IN, USA
- 700 1_
- $a Barrett, Emily $u Eli Lilly and Company, Indianapolis, IN, USA
- 700 1_
- $a Cao, Shanshan $u Eli Lilly and Company, Indianapolis, IN, USA
- 700 1_
- $a Wang, Xuejing Aimee $u Eli Lilly and Company, Indianapolis, IN, USA
- 700 1_
- $a Smyth, Lillian $u Eli Lilly and Company, Indianapolis, IN, USA
- 700 1_
- $a Bidard, Francois-Clement $u Institute Curie and UVSQ/Paris-Saclay University, Paris and Saint Cloud, France
- 773 0_
- $t Prague Onco Journal $x 1804-2252 $g Roč. 2025, č. 1 (2025), s. 51-52 $w MED00177652
- 910 __
- $a ABA008 $b B 2634 $c 664 $y p $z 0
- 990 __
- $a 20250924151722 $b ABA008
- 991 __
- $a 20251008150214 $b ABA008
- 999 __
- $a ok $b bmc $g 2405982 $s 1258393
- BAS __
- $a 6
- BMC __
- $a 2025 $b 2025 $c 1 $d 51-52 $i 1804-2252 $m Prague Onco Journal $n Prague Onco J. $x MED00177652
- LZP __
- $a NLK 2025-04/dnbi
